First Trade Date for Millennium Pharmaceuticals, Inc.
|Company Name||First Trade Date (yyyy-mm-dd)|
|Millennium Pharmaceuticals, Inc.||1996-05-07|
|Millennium Pharmaceuticals, Inc.||MLNM|
|History and Business of Company|
(this information may include date of incorporation)
Millennium Pharmaceuticals, Inc. (MLNM) incorporates large-scale genetics, genomics, high throughput screening, and informatics in an integrated science and technology platform. MLNM applies this technology platform primarily in discovering and developing proprietary therapeutic and diagnostic human healthcare products and services.|
MLNM uses many technologies in each step of the therapeutic and diagnostic product discovery and development processes. The company seeks the most advanced methods available to integrate into its technology platform, whether developed internally or licensed from third parties in order to increase the efficiency and productivity of these processes. MLNM believes that its platform will enable the company to identify commercially important genes; elucidate their functions; validate targets for product development; and identify and develop drug and diagnostic candidates for clinical development.
MLNM has three fields of major emphasis: cancer, metabolic diseases (including obesity) and inflammation. The company also has significant programs in infectious diseases, cardiovascular diseases and diseases of the central nervous system. MLNM seeks to discover disease-related genes, produce validated drug targets and drug leads, and develop new, proprietary drugs to treat major human illnesses. The company also focuses on developing small- molecule drugs, which are typically formulated into pills for oral consumption, as well as proteins and monoclonal antibodies, which are typically only available in injectable form.
Through its wholly owned subsidiary, Millennium Preventive Medicine, Inc. (MPMx), the company seeks to develop products and services that will provide clinicians and pharmaceutical researchers with information that enables them to make better informed decisions about drug treatment and other aspects of patient management. MLNM's core areas of focus include Diagnomics products and pharmacogenomics. A Diagnomics product is a gene- based diagnostic test to determine the patient's medical status and facilitate cost-effective treatment. Pharmacogenomics is the identification of genes, or their activity, associated with responsiveness to particular drugs.
In April 2001, MLNM announced an agreement with BZL Biologics, L.L.C. to jointly develop antibody-based therapeutics targeting Prostate Specific Membrane Antigen, a molecule associated with prostate cancer.
INCORPORATED in Delaware in January 1993. OFFICE- 75 Sidney St. , Cambridge, MA 02139 (Tel.: 617-679-7000). Fax - 617-374-9379. WEBSITE-http://www.millennium.com.
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, The Magi Associates, Inc. and Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
Back to home page
© 1999-2004 by Magi Associates, Inc. and Magi Astrologers Worldwide Corporation. All Rights Reserved.
Magi Astrology is a trademark and service mark of THE MAGI ASSOCIATES, INC.